Gilbert & Cook Inc. Purchases 40 Shares of Eli Lilly and Company (NYSE:LLY)

Gilbert & Cook Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,783 shares of the company’s stock after acquiring an additional 40 shares during the quarter. Gilbert & Cook Inc.’s holdings in Eli Lilly and Company were worth $1,472,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Garner Asset Management Corp boosted its stake in Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 12 shares in the last quarter. Applied Finance Capital Management LLC boosted its stake in Eli Lilly and Company by 1.4% in the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock worth $660,000 after purchasing an additional 12 shares in the last quarter. Tobias Financial Advisors Inc. boosted its stake in Eli Lilly and Company by 4.1% in the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company’s stock worth $237,000 after purchasing an additional 12 shares in the last quarter. Redwood Investments LLC boosted its stake in Eli Lilly and Company by 0.5% in the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company’s stock worth $1,705,000 after purchasing an additional 12 shares in the last quarter. Finally, Hobbs Wealth Management LLC boosted its stake in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after purchasing an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Guggenheim lifted their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Wall Street Zen cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Saturday, June 28th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,012.56.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $804.74 on Friday. The business has a 50 day simple moving average of $770.86 and a two-hundred day simple moving average of $800.14. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a market capitalization of $762.69 billion, a P/E ratio of 65.48, a PEG ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company earned $2.58 EPS. Eli Lilly and Company’s revenue was up 45.2% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.75%. Eli Lilly and Company’s payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.